RECOMMENDATION

It is recommended to perform a case series study extending for 6-12 months on the pain relieving effect, tolerability and side effects of diacerein in OA patients.

ANNEXES

Annex (1)

Pain Visual Analogue Scale (VAS) [170]

0 - 10 VAS



Description

Purpose: The pain VAS is a unidimensional measure of pain intensity, which has been widely used in diverse adult populations, including those with rheumatic diseases.

Content: The pain VAS is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. Instructions, time period for reporting, and verbal descriptor anchors have varied widely in the literature depending on intended use of the scale.

Number of items: The pain VAS is a single-item scale.

Response options/scale: For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 [100-mm scale]). To avoid clustering of scores around a preferred numeric value, numbers or verbal descriptors at intermediate points are not recommended.

Recall period for items: Varies, but most commonly respondents are asked to report "current" pain intensity or pain intensity "in the last 24 hours."

Practical Application:

How to obtain: The pain VAS is available in the public domain at no cost. Graphic formats for the VAS may be obtained from Scott & Huskisson or online: http:// www.amda.com/tools/library/whitepapers/hospiceinltc/appendix-a.pdf.

Method of administration: The pain VAS is selfcompleted by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity.

Scoring: Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0–100.

Score interpretation: A higher score indicates greater pain intensity. Based on the distribution of pain VAS scores in postsurgical patients (knee replacement, hysterectomy, or laparoscopic myomectomy) who described their postoperative pain intensity as none, mild, moderate, or severe, the following cut points on the pain VAS have been recommended: no pain (0–4 mm), mild pain (5–44mm), moderate pain (45–74 mm), and severe pain (75–100 mm). Normative values are not available.

Respondent burden: The VAS takes <1 minute to complete.

Administrative burden: The VAS is administered as a paper and pencil measure. As a result, it cannot be administered verbally or by phone. No training is required other than the ability to use a ruler to measure distance to determine a score. Caution is required when photocopying the scale as this may change the length of the 10-cm line. As slightly lower scores have been reported on the HVAS compared to the VVAS, the same alignment of scale should be used consistently within the same patient.

Translations/adaptations: Minimal translation difficulties have led to an unknown number of cross-cultural adaptations.

Psychometric Information

Method of development: The pain VAS originated from continuous visual analog scales developed in the field of psychology to measure well-being. Woodforde and Merskey first reported use of the VAS pain scale with the descriptor extremes "no pain at all" and "my pain is as bad as it could possibly be" in patients with a variety of conditions. Subsequently, others reported use of the scale to measure pain in rheumatology patients receiving pharmacologic pain therapy. While variable anchor pain descriptors have been used, there does not appear to be any rationale for selecting one set of descriptors over another.

Acceptability: The pain VAS requires little training to administer and score and has been found to be acceptable to patients. However, older patients with cognitive impairment may have difficulty understanding and therefore completing the scale. Supervision during completion may minimize these errors.

Reliability: Test–retest reliability has been shown to be good, but higher among literate (r = 0.94, $P < 0.001$) than illiterate patients (r = 0.71, $P < 0.001$) before and after attending a rheumatology outpatient clinic.

Validity: In the absence of a gold standard for pain, criterion validity cannot be evaluated. For construct validity, in patients with a variety of rheumatic diseases, the pain VAS has been shown to be highly correlated with a 5-point verbal descriptive scale ("nil," "mild," "moderate," "severe," and "very severe") and a numeric rating scale (with response options from "no pain" to "unbearable pain"), with correlations ranging from 0.71–0.78 and 0.62–0.91, respectively). The correlation between vertical and horizontal orientations of the VAS is 0.99.

Ability to detect change: In patients with chronic inflammatory or degenerative joint pain, the pain VAS has demonstrated sensitivity to changes in pain assessed hourly for a maximum of 4 hours and weekly for up to 4 weeks following analgesic therapy ($P < 0.001$). In patients with rheumatoid arthritis, the minimal clinically significant change has been estimated as 1.1 points on an 11-point scale (or 11 points on a 100-point scale). A minimum clinically important difference of 1.37 cm has been determined for a 10-cm pain VAS in patients with rotator cuff disease evaluated after 6 weeks of nonoperative treatment.

Critical Appraisal of Overall Value to the

Rheumatology Community

Strengths/caveats and cautions/clinical and research

Usability: The VAS is widely used due to its simplicity and adaptability to a broad range of populations and settings. Its acceptability as a generic pain measure was demonstrated in the early 1970s. Limitations to the use of the pain VAS include the following: older patients may have difficulty completing the pain VAS due to cognitive impairments or motor skill issues, scoring is more complicated than that for the Numeric Rating Scale for pain (described below), and it cannot be administered by telephone, limiting its usefulness in research.

Annex (2)

Pain Verbal Rating Scale (VRS) [171]



The VRS comprises a list of adjectives used to denote increasing pain intensities. The most common words used being: no pain; mild pain; moderate pain; and severe or intense pain. For ease of recording these adjectives are assigned numbers. These rank numbers can lead to the misapprehension that intervals between each descriptor are equal, but this is not the case and could be a source of error. The VRS is ordinal. There is no published evidence about the distribution of data obtained from the VRS. In most cases, data collected using a VRS can only be analysed using non-parametric statistics.

REFERENCES

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected muscoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778-799.

2. Arden N, Nevitt MC. Osteoarthritis epidemiology. Best Pract Clin Rheumatol 2006; 20(1): 3-25.

3. Buckwalter JA, Mankin HJ: Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course lect 1998; 47:487-504.

4. Buckwalter JA, Martin J, Mankin HJ: Synovial joint degeneration and the syndrome of osteoarthritis. Instr Course Lect 2000; 49:489.

5. Goldring MB: the role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000, 43:1916-26.

6. Punzi L, Calo L, Plebani M. Clinical Significance of Cytokine Determintion in Synovial Fluid. Critical Reviews in Clinical Laboratory Sciences 2002; 39: 63-88.

7. Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin 1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998; 41: 1083-9.

8. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95.

9. Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.J Rheumatol 1995; 22: 406-12.

10. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.

11. Tatakis DN. Interleukin-1 and bone metabolism: a review. J Periodontol 1993; 64: 416-31.

12. Chandrasekhar S, Harvey AK, Higginbotham JD, Horton WE. Interleukin-1 - induced suppression of type II collagen gene transcription involves DNA regulatory elements. Exp cell Res 1991; 191: 105-14.

13. Shlopov BV,Lie WR, Mainardi CL, et al. osteoarthritis lesions: Involvement of different collagenases. Arthritis Rheum 1997; 40:2065-74.

14. Treadwell BV, Pavia M, Towle CA, Cooley VJ, Mankin HJ. Cartilage synthesizes the serine protease inhibitor PAL-1: Support for the involvement of serine proteases in cartilage remodeling. J Orthop Res 1992; 9:309-16.

15. Treadwell BV, Towle CA, Ishizue K, et al.Stimulationof the synthesizes of collagenase activator protein in cartilage by a factor present in synovial-conditioned medium. Arch Biochem Biophys 1986; 251:724-731.

16. Tyler JA. Articular cartilage cultured with catabolin (pig Interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem J 1985; 227:869-78.

17. Tyler JA, Benton HP. Synthesis of type II collagen is decreaed in cartilage cultured with Interleukin 1 while the rate of intracellular degradation remains unchanged. Coll Relat Res 1988; 8:393-405.

18. Van Beuningen HM, Arntz OJ, van den Berg WB. In vivo effects of Interleukin-1 on articular cartilage: prolongation of proteoglycan metabolic disturbances in old mice. Arthritis Rheum 1991; 34:606-15.

19. Woessner Jr JF, Gunja-Smith Z. Role of metalloproteinases in human osteoarthritis. J Rheumatol Suppl 1991; 27:99-101.

20. Kobayashi M, Squires GR, Mousa A, Tanzer M, Zukor DJ, Antoniou J, et al. Role of Interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage.Arthritis Rheum 2005;52(1):128-35.

21. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res2004; S27-S36. Full Text via CrossRef |View Record in Scopus|Cited By in Scopus (113).

22. Massoud D, Yao JQ. The Interleukin-1b pathway in the pathogenesis of osteoarthritis. J Rhaumatil 2008; 35: 2306-12

23. Mahajan A, Singh K, Tandon VR, Kumar S, Kumar H. Diacerein: A New Symptomatic Slow Acting Drug for Osteoarthritis. JK Science, Journal of Medical Education & Research 2006; 8:173-175.

24. Mendes AF, Caramona MM, de Carvalho AP, Lopes MC. Diacerhein and rhein prevent Interleukin-1B-induced nuclar factor-kB activation by inhibiting the degradation of inhibitor kB-a. Pharmacol Toxicol 2002; 91:22-8.

25. Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (oxford) 2006; 45(2): 129-38. Epub 2005 Nov 8.

26. Fidelix TSA, Soares B, Trevirani FM. Diacerein for Osteoarthritis. Cochrane review. Available at http://www.cochrane.org/reviews/en/ ab005117.html 2006; 25.

27. Yang KGA, Raijmakers NJH, van Arkel ERA, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis and Cartilage 2008; 16(4): 498-505.

28. Martel J, Pelletier JP. The cytokine network in Osteoarthritis. Reumatologia 2003; 19(2): 89-92.

29. Peter M, Kraan V, van den Berg WB. Anabolic and destructive mediators in Osteoarthritis. Current Opinion in Clinical Nutrition and metabolic care 2000; 3:205-211.

30. Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Caspian J Intern med 2011; 2(2): 205-12.

31. Bliddal H, Christensen R. The treatment and prevention of knee osteoarthritis: a tool for clinical decision-making. Expert Opin pharmacother 2009; 10:1793-804.

32. Hayami T. Osteoarthritis of knee joint as a cause of musculoskeletal ambulation disability symptom complex (MADs). Clin Calcium 2008; 18:1574-80.

33. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010; 26: 355-69.

34. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001; 60: 91-7.

35. Srikanth VK, Fryer JL, Zhai G, et al. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage 2005; 13:769-81.

36. Sowers M, Karvonen-Gutierrez CA, Jacoboson JA, Jiang Y Yosef M. Associtations of anatomical measures from MRI with radiographically defined knee osteoarthritis score, pain and physical functioning. J bone joint Surg Am 2011; 93:241-51.

37. Ortner DJ. Identification of Pathological Conditions in Human Skeletal Remains. Academic Press. San Diego, CA. 2003

38. Rogers J, Waldron T. A Field Guide to Joint Disease in Archaeology. John Wiley: New York. 1995.

39. Jurmain R. Stories from the Skeleton: Behavioral Reconstruction in Human Osteology. Gordon and Breach Publishers. Greensboro, N.C. 1999.

40. Larsen CS. Bioarchaeology: Interpreting behavior from the human skeleton Cambridge. Cambridge University Press. 1997.

41. Weiss E, Jurmain R. Osteoarthritis Revisited: A contemporary Review of Aetiology. International Journal of Osteoarchaeology 2007; 17:437-50.

42. Waldron T. Paleopathology. Cambridge Manuals in Archaeology. Cambridge press. 2000.

43. Blagojevic M, Jinks C, Jeffery A, Jordan KP. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 2010; 18:24-33.

44. Reid CR, Bush PM, Cummings NH, McMullin DL, Durrani SK. A review of occupational knee disorders. J Occup Rehabil 2010; 20:489-501.

45. Lementowski PW, Zelicof SB. Obesity and osteoarthritis. Am J Orthop (Belle Mead NJ) 2008; 37:148-51.

46. Zhang Y, Hunter DJ, Nevitt MC, et al. Association of squatting with increased prevalence of radiographic tibiofemoral knee osteoarthritis: the Beijing Osteoarthritis Study. Arthritis Rheum 2004; 50: 1187-92.

47. Yoshimura N, Muraki S, Oka H, et al. Association of Knee Osteoarthritis with the Accumulation of Metabolic Risk Factors Such as Overweight, Hypertension, Dyslipidemia, and Impaired Glucose Tolerance in Japanese Men and Women: The ROAD Study. J Rheumatol 2011; 35: 921-30.

48. Behzad-Heidari MD. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Caspian J Intern Med 2011; 2(2): 205–12.

49. Grazio S, Balen D. Obesity: Risk factor and predictors of osteoarthritis. Lijec Vjesn 2009;131(1-2):22-6.

50. Nicholoson S, Dickman K, Maradiegue A. Reducing premature osteoarthritis in the adolescent through appropriate screening. J Pediatr Nurs 2009; 24:69-74.

51. Magnussen RA, Mansour AA, Carey JL, Spindler KP. Meniscus status at anterior cruciate ligament reconstruction associated with radiographic signs of osteoarthritis at 5- to 10-years follow-up: a systematic review. J Knee Surg 2009; 22: 347-57.

52. Martel-Pelletier J, Pelletier JP. Is osteoarthritis a disease involving only cartilage or other articular tissues?. Eklem Hastalik Cerrahisi 2010; 21:2-14.

53. Wolfe F. The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol1997; 24:1486-8.

54. Takahashi M, Naito K, Abe M, Sawada T, Nagano A. Relationship between radiographic grading of osteoarthritis and the biochemical markers for arthritis in knee osteoarthritis. Arthritis Res Ther 2004; 6: R208-12.

55. Teichtahl AJ, Wluka AE, Proietto J, Cicuttini FM. Obesity and the female sex, risk factors for knee osteoarthritis that may be attributable to systemic or local leptin biosynthesis and is cellular effects. Med Hypotheses 2005; 65: 312-5.

56. Heidari B, Hajian K. previous pregnancies and subsequent risk of knee osteoarthritis. J Res Med Sci 2000; 2: 71-8.

57. Sigal LH. Basic Science for the Clinician 33. Interleukins of Current Clinical Relevance (Part 1). Journal of Clinical Rheumatology 2004; 10(6):353-9.

58. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: WJ Koopman, editors. Williams& Allied conditions. A Textbook of Rheumatology. Baltimore, Williams & Wilkins; 2001,p. 2195-2245.

59. Martel-Pelletier J, Alaaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Bioscl 1999; 4:D694-703.

60. Caron JP, Fernandes JC, Martel- Pelletier J, Tardef G, Mineau F, Geng C, et al. chondroprotective effect of injections of Interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996; 39:1535-44.

61. Van de Loo FA, Joosten LA, Van Lent PL, Arntz OJ, Van den Berg WB. Role of Interleukin-1, tumor necrosis factor alpha, and Interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ bloking in murine antigen –and zymosan-induced Arthritis. Arthritis Rheum 1995; 38:164-72.

62. Plows D, Probert L, Georgopoulos S, Alexopoulou L, Kollias G. The role of tumour necrosis factor (TNF) in Arthritis: studies in transgenic mice. Rheumatol Eur 1995; 2(Suppl):51-4.

63. Amin AR. Type II Interleukin-1B Receptor: A Candidate for Gene Therapy in Human Arthritis. Clincal Orthopaedics and Related Researsh 2000; 379S; S179-S88.

64. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 2004; 3:330-9.

65. Saha N, Moldovan F, Tardif G, Pelletier JP, Cloutier Jm, Martel- Pelletier J. Interleukin-1B-converting enzyme ⁄caspase-1 in human osteoarthritis tissues: localization and role in the maturation of Interleukin-1B and Interleukin-18 Arthritis Rheum 1999; 42:1577-87.

66. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24: 365-71.

67. Kubota E, Imamura H, Kubote H, Shibata T, Murakami K. Interleukin 1 beta and stormelysin (MMP3) activity of Synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg 1997; 55:20-7.

68. Loser RF, Carlson CS, Del Carlo M, Cole A. Detection of nitrotyrosine in aging and osteoarthritis cartilage: Correlation of Oxidative damage with the presence of Interleukin-1B and with chondrocyte resistance insulin-like growth factor1.Arthritis Rheum 2002; 46:2349-57.

69. Pelletier JP, McCollum R, Cloutier JM, Martel-Pelletier J. Synthesis of metalloproteases and Interleukin-6(IL-6) in human osteoarthritis synovial membrane is an IL-1 mediated process. J Rheumatol 1995; 22 (Suppl43):109-14.

70. Marks PH, Donaldson ML. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy 2005; 21:1342-7.

71. Shlopov BV, Gumanovskaya ML, Hasty KA. Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis. Arthritis Rheum 2000; 43:195-205.

72. Aigner T, McKenna L, Zien A, Fan Z, Gebhard PM, Zimmer R. Gene expression profiling of Serum- and Interleukin-1B stimulated primary human adult articular chondrocytes – a molecular analysis based on chondrocytes isolated from one donor. Cytokine 2005; 31:227-40.

73. Aigner T, Fundel K, Saas J, et al. large-scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis. Rheum 2006; 54:3533-44.

74. Fan Z, Soder S, Oehler S, Fundel K, Aigner T. Activation of Interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. Am J Pathol 2007; 171:938-46.

75. Saas J, Haag J, Rueger D, et al. IL-1B, but not BMP-7 leads to a dramatic change in the gene expression pattern of human adult articular chondrocytes-portraying the gene expression pattern in two donors. Cytokine 2006; 36:90-9.

76. Sadouk MB, Pelletier JP, Tardif G, Kiansa K, Cloutier JM, Martel Pelletier J. Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Lab Invest 1995; 73:347-55.

77. Fernandes JC, Martel Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39:237-46.

78. Loughlin J, Dowling B, Mustafa Z, Chapman K. Association of the Interleukin-1 gene cluster on chromosome 2q13 with knee osteoarthritis. Arthritis Rheum 2002; 46:1519-27.

79. Pelletier JP, Lascau-Coman V, Jovanovic D, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue level of catabolic factors. J Rheumatol 1999; 26:2002-14.

80. Wheaton AJ, Borthakur A, Dodge GR, Kneeland JB, Schumacher HR, Ready R. Sodium magnetic resonance imaging of proteoglycan depletion in an in vivo model of osteoarthritis. Acad Radiol 2004; 11:12-8.

81. Lai Yc, Shaftel SS, Miller JN, et al. Intraarticular induction ofInterleukin-1B expression in the adult mouse with resultant temporomandibular joint pathologic changes, dysfunction, and pain. Arthritis Rheum 2006; 54:1184-97.

82. Fan Z, Bau B, Yang H, Soeder S, Aigner T. Freshly isolated osteoarthritic chondrocytes are catabolically more active than normal chondrocytes, but less responsive to catabolic stimulation with interleukin-1β. Arthritis Rheum 2005; 52:136-43.

83. Elliott S, Hays E, Mayor M, Sporn M, Vincenti M. The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes. Arthritis Res Ther 2003; 5:R285-91.

84. Inoue K, Masuko-Hongo K, Okamoto M, Nishioka K. Induction of vascular endothelial growth factor and matrix metalloproteinase-3 (stromelysin) by interleukin-1 in human articular chondrocytes and synoviocytes. Rheumatol Int 2005; 26:93-8.

85. Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor α in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005; 52:128-35.

86. Mix KS, Mengshol JA, Benbow U, Vincenti MP, Sporn MB, Brinckerhoff CE. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum 2001; 44: 1096-104..

87. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001; 44:585-94.

88. Bondeson J, Lauder S, Wainwright S, et al. Adenoviral gene transfer of the endogenous inhibitor IkBa into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kB-dependent. J Rheumatol 2007; 34:523-33.

89. Cortial D, Gouttenoire J, Rousseau CF, et al. Activation by IL-1 of bovine articular chondrocytes in culture within a 3D collagen-based scaffold. An in vitro model to address the effect of compounds with therapeutic potential in osteoarthritis. Osteoarthritis Cartilage 2006; 14:631-40.

90. Dia SM, Shan ZZ Nishioka K,Yudoh K. Implication of interleukin 18 in productionof matrix metalloproteinases in articular chondrocytes in arthritis direct effect on chondrocytes may not be pivotal. Ann Rheum Dis 2005; 64:735-42.

91. Mehraban F, Tindal MH, profit MM, Moskowitz RW. Temporal pattern of cysteine endopeptidase (cathepsin B) expression in cartilage and synovium from rabbit knee with experimental osteoarthritis: gene expression in chondrocytes in response to interleukin-1 and matrix depletion. Ann Rheum Dis 1997; 56:108-15.

92. Milner JM, Kevorkian L, Young DA, et al Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis.Arthritis Res Ther 2006; 8:R23.

93. Schwab W, Schulze-Tanzil G, Mobasheri A, Dressler J, Kotzsch M, shakibaei M. interleukin-1B-induced expression ofthe urokinase-type plasminogen activator receptor and its co-localization with MMPs in human articular chondrocytes. Histol Histopathol 2004; 19:105-12.

94. Shikhman AR, Brinson DC, Lotz M. Profile of glycosaminoglycan-degrading glycosidases and glycoside sulfatases secreted by human articular chondrocytes in homeostasis and inflammation. Arthritis Rheum 2000; 43; 1307-14.

95. Nakamura H, Yoshino S, Kato T, Tsuruha J, Nishioka K. T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthritis cartilage 1999; 7:401-2.

96. Da RR, Kao G, Guo WZ, et al. polyclonal B-Cell expansion in the cerebrospinal fluid of patients with pseudotumor cerebri. J Clin Immunol 2004; 24:674-82.

97. Walsh DA, Bonnet CS, Turner EL, Wilson D, Situ M, Mc Williams DF. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage 2007; 15:743-51.

98. Blom AB, Van Lent PL, Holthuysen AE, et al. Synovial lining macrophages mediate osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartilage 2004; 12:627-35.

99. Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006; 8:R187.

100. Pfander D, Heinz N, Rothe P, Carl HD, Swoboda B. Tenascin and aggrecan expression by articular chondrocytes is influenced by interleukin 1β: a possible explanation for the changes in matrix synthesis during osteoarthritis. Ann Rheum Dis 2004; 63:240-4.

101. Stove J, Huch K, Gunther KP, Scharf HP. Interleukin-1β induces different gene expression of stromelysin, aggrecan and tumor necrosis factor-stimulated gene 6 in human osteoarthritic chondrocytes in vitro. Pathobiology 2000; 68:144-9.

102. Venkatesan N, Barre L, Benani A, et al. Stimulation of proteoglycan synthesis by glucuronosyltransferase-I gene delivery: a strategy to promote cartilage repair. Proc Natl Acad Sci USA 2004; 101:18087-92.

103. Eger W, Schumacher BL, Mollenhauer J, Kuettner KE, Cole AA. Human knee and ankle cartilage explants: catabolic differences. J Orthop Res 2002; 20:526-34.

104. Attur MG, Dave MN, Clancy RM, Patel IR, Abramson SB, Amin AR. Functional genomic analysis in arthritis-affected cartilage: yin-yang regulation of inflammatory mediators by alpha 5 beta 1 and alpha V beta 3 integrins. J Immunol 2000; 164:2684-91.

105. Stabellini G, De Mattei M, Calastrini C, et al. Effects of interleukin-1β on chondroblast viability and extracellular matrix changes in bovine articular cartilage explants. Biomed Pharmacother 2003; 57:314-9.

106. Gouze JN, Bordji K, Gulberti S, et al. Interleukin-1β down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β-mediated effects in rat chondrocytes. Arthritis Rheum 2001; 44:351-60.

107. Shakibaei M, John T, Seifarth C, Mobasheri A. Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro. Ann NY Acad Sci 2007; 1095:554-63.

108. Yudoh K, Shishido K, Murayama H, et al. Water-soluble C60 fullerene prevents degeneration of articular cartilage in osteoarthritis via down-regulation of chondrocyte catabolic activity and inhibition of cartilage degeneration during disease development. Arthritis Rheum 2007; 56:3307-18.

109. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988; 82:2026-37.

110. Nawrat P, Surazynski A, Karna E, Palka JA. The effect of hyaluronic acid on interleukin-1-induced deregulation of collagen metabolism in cultured human skin fibroblasts. Pharmacol Res 2005; 51:473-7.

111. Lopez-Armada MJ, Carames B, Lires-Dean M, et al. Cytokines, tumor necrosis factor-α and interleukin-1β, differentially regulate apoptosis in osteoarthritis cultured human chondrocytes. Osteosrthritis Cartilage 2006; 14:660-9.

112. Heraud F, Heraud A, Harmand MF. Apoptosis in normal and osteoarthritic human articular cartilage. Ann Rheum Dis 2000; 59:959-65.

113. Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Palletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage 1996; 4:77-84.

114. Tenor H, Hedbom E, Hauselmann HJ, Schudt C, Hatzelmann A. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes−functional importance of phosphodiesterase 4. Br J Pharmacol 2002; 135:609-18.

115. Clancy R, Rediske J, Koehne C, et al. Activation of stress-activated protein kinase in osteoarthritic cartilage: evidence for nitric oxide dependence. Osteoarthritis Cartilage 2001:9; 294-9.

116. Dougados M. Why and How to use NSAIDs in Osteoarthritis.J Cardiovasc Phamacol 2006; 47 (Suppl 1):S49-S54.

117. Ayral X, Dougados M, Listrat V, et al.Chondroscopy: a new method for scoring chondropathy. Semin Arthritis Rheum 1993; 22:289-97.

118. Dougados M, Ayral X, Lisrat V, et al. The SAF system for assessing articular cartilage lesions arthroscopy of the knee. Arthroscopy1994; 10:69-77.

119. Ayral X, Gueguen A, Listrat V, et al. Simplified osteoarthritis scoring system for chondropathy of the knee (revised SFA score). Rev Rhum (Engl Ed)1994; 61:88-90.

120. Ayral X, Dougados M, Listrat V, et al. Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J Rheumatol 1996; 23:698-706.

121. Royle SG, Noble J, Davies P. Significance of chondromalacia changes on the patella. Arthroscopy 1991; 7:158-160.

122. Mazieres B, Blanckaert A, Thiechart M. Experimental post-contusive osteoarthritis of the knee: quantitative microscopic study of the patella and the femoral condyles. J Rheumatol 1987; 14(Suppl 4): 119-21.

123. Altman R, Asch E, Bloch G, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29:1039-49.

124. Zhang W, Doherty M, Peat G, et al. EULAR evidence-based recommendation for the diagnosis of knee osteoarthritis. Ann Rheum Dis 2010; 69:483-9.

125. Heidari B. Rheumatic diseases. 1st ed. Babol; Iran Babol University of Medical Sciences Publication, 2002.

126. Conaghan PG, Felson DT. Structural associations of osteoarthritis pain: lessons from magnetic resonance imaging. Novartis Found Symp 2004; 260: 191-201; discussion 201-5,277-9.

127. Wenham CY, Conaghan PG. Imaging the painful osteoarthritis knee joint: what have we learned?. Nat Clin Pract Rheumatol 2009; 5:149-58.

128. Garnero P, Peterfy C, Zaim S, Schoenhating M. Bone marrow abnormalities on magnetic resonance imaging are associatedwith type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005; 52: 2822-9.

129. Hayes CW, Jamadar DA, Welch GW, et al. Osteoarthritis of the knee: comparison of MR imaging finding with radiographic severity measurements and pain in middleaged Women. Radiology 2005; 237:998-1007.

130. Lotz M. Cytokines in Cartilage Injury and Repair. Clinical Orthopaedics and Related Research 2001;391S: S108-S15.

131. Murata M, Trahan C, Hirahashi J, Mankin HJ, Christine A. Towle. Intracellular Interleukin-1 Receptor Antagonist in Osteoarthritis Chondrocytes. Clinical Orthopaedics and Related Research 2003; 409: 285-95.

132. Hogenmiller MS, Lozada CJ. An update on osteoarthritis therapeutics. Curr Opin Rheumaatol 2006; 18:256-60.

133. Margriet E, Baar V, Assendelft WJ, Dekker J, Oostendorp RA, Johannes WJ. Blilsma. Effectiveness of Exercise Therapy in patients with Osteoarthritis of the Hip or Knee. Arthritis & Rheumatism 1999; 42(7):1361-9.

134. Dekker J, Boot B, van der Woud L, Bijlsma JW. Pain and disability in osteoarthritis: a review of biobehavioral mechanisms. J Behav Med 1992; 15:189-241.

135. Messier SP, loeser RF, Mitchell MN, et al Exercise and weight loss in obese older adults with knee osteoarthritis: a preliminary study. J Am Geriatr Soc 2000; 48:1068-72.

136. Christensen R, Astrup A, Bliddal H, et al. Suatained weight loss as a treatment of osteoarthritis in obese patients: long-term results from a randomized trial. Ann Rheum Dis 2005; 64 (suppl III):66.

137. Christensen R, Astrup A, Bliddal H, et al. Weight loss: the treatment of choice for knee osteoarthritis? A randomized trial. Osteoarthritis Cartilage 2005; 13:20-27.

138. Messier SP, Loeser Rf, Miller GD, et al. Exercise and dietary Weight loss in overweight and obese older adults with knee osteoarthritis. The arthritis, diet and activity promotion trial. Arthritis Rheum 2005; 50:1501-10.

139. Solomon SD, McMmurrray JV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxid in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-80.

140. Pelletier JP, Martel-pelletier J. Effects of minesulfide and naproxem on the degradation and metalloprotease synthesis of human osteoarthritis cartilage. Drugs 1993; 46:34-9.

141. Pelletier JP, Mineau F, Fernandes J, et al. Tow NSAIDs, minesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAL-1 in human OA synovial fibroblasts. Clin EXP Rheumatol 1997; 15:393-8.

142. Hyskinsson EC, Berry H, Gishen P, et al. On behalf of the LINK Study Group. Effect of anti-inflammatory drugs on the progression osteoarthritis of the knee. J Rheumatol 1995; 22:1941-6.

143. Rashad S, Revel P, Geminghway A, et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; 1:519-22.

144. Williams HJ, Ward R, Egger MJ, et al. Comparison of naproxen and acetaminophen in a tow-year study of treatment of osteoarthritis of the knee. Arthritis Rheum1993; 36:1196-206.

145. Dieppe P, Cushnaghan J, Jasani MK, et al. A two-year, placebo-controllrd trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint. Br J Rheumatol 1993; 32:595-600.

146. Buckland-Wright JC, McFarkabe DG, Lynch JA, et al. Quantitative microfocal radiography detects changes in osteoarthritis knee joint space width in patients in placebo controlled trial of NSAID therapy. J Rheumatol 1995; 22:937-43.

147. Garcia Rodriguez LA, Hernandez-Diaz S. The relative risk of upper gastrointestinal complication among users of acetaminophen and non-steroidal anti- inflammatory drugs. Epidemiology 2001; 12:570-6.

148. Mends AF, Caramona MM, de Carvalho AP, Lopes MC. Diacerhein and rhein prevent interleukin-1β-induced nuclear factor-kB activation by inhibiting the degradation of inhibitor kB-a. Pharmacol Toxicol 2002; 91:22-8.

149. Felisaz N, Boumediene K, Ghayor C, et al. Stimulating effect of Diacerein on TGF-beta 1 and beta 2 expression in articulate chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage 1999; 7(3): 255-64.

150. Solignac M. Mechanisms of action of diacerein the first inhibitor of interleukin-1 in Osteoarthritis. Presse Med 2004; 33:S10-2.

151. Spencer CM, Wilde MI. Diacerein. Drugs 1997; 53(1):98-106;107-8.

152. Colville-Nash PR. Comparison of pharmacological effect of diacerein and a selective COX-2 inhibitor in mouse induced glaucoma model. Presse Med 2002; 31(39pt2):4S16-7.

153. Nicholas P, Tod M, Padion C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet 1998; 35(5)347-59.

154. Magnard O, Louchahi K, Tod M, et al. Pharmacokinetics of diacerein in patients with liver cirrhosis. Biopharm Drug Dispos 1993; 14(5):401-8.

155. Taccoen A, Berdah L. Diacetylrhein, a new therapeutic approach of osteoarthritis. Rev Rhum Ed Fr 1993; 60(6 Pt 2):83S-6S.

156. Pelletier JP, Yaron M, Haroui B, et al. Efficacy and safety of diacerein in osteoarthritis of knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000; 43(10):2339-48.

157. Nguyen M, Dougados M, Berdah L, et al. Diacerein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994; 37:529-36.

158. Lequesne M, Berdah L, Gerentes I. Efficacy and tolerance of diacerein in the treatment of gonarthrosis and coxarthrosis. Rev Prat 1998; 48:31-5.

159. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001; 357:251-6.

160. Dougados M, Nguyen M, Berdah L, et al. For the ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis. ECHODIAH, a 3-year placebo-controlled trial. Arthitis Rheum 2001; 44: 2539-47.

161. Louthrenoo W, Nilganuwong S, Aksaranugraha S, Apavatanabodee P, Saengnipanthkul S. The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomized, double-blind, NSAID-controlled study. Osteoarthritis and Cartilage 2007; 15:605-14.

162. Baliga VP, Jagiasi JD, Arun Kumar MS, Sankaralingam K, Veerappan V, Bolmall CS. Efficacy, safety and tolerability of diacerein MR 100 mg vs diacerein 50 mg in adult patients with osteoarthritis of the knee. Osteoarthritis and Cartilage 2010; (Suppl 2):S45-S26.

163. Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. International Journal of Rheumatic Diseases 2012; 15: 69-77.

164. Zheng WJ, Tang FL, Li J, Zhang FC, Li ZG, Su Y, et al. Evaluation of efficacy and safety of diacerein in knee osteoarthritis in Chinese patients. Chin Med Sci J 2006; 21(2):75-80.

165. Moldovan F, Pelletier J, Jolicoeur CF, Cloutier JM, Martel-pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1β and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis and Cartilage 2000; 8: 186-96.

166. de Isia N, Burger M, Stoltz JF. In vitro effects of diacerhein on IL-1β stimulated chondrocytes analysed by confocal microscopy. Osteoarthritis and Cartilage 2007; 15: C129.

167. Leeb BF. Symptomatic slow acting drugs in osteoarthritis: Workshop and Panel dicussion: What is the evidence? Diacerein in osteoarthritis. Osteoarthritis and Cartilage 2006; 14(Suppl B):S14-S5.

168. Bartels EM, Bliddal H, Schøndorff PK, Altman RD, Zhang W, Christensen R.Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010; 18(3):289-96.

169. Fidelix TS.A., Macedo CR, Maxwell LJ, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. *Cochrane Database of Systematic Reviews* 2014, Vol: 10 (Issue 2). Art. No.: CD005117. DOI: 10.1002/14651858.CD005117.pub3.

170. Hawker GA, Mian S, Kendzerska T, Frenc M. Measures of adult pain. Arthritis Care & Research 2011; 63(Suppl 11):S240-S52.

171. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. Journal of Clinical Nursing 2005; 14:798-804.

الملخص العربى

الهدف من البحث هو دراسة تأثير عقار دياسيرين على آلام الركبة وشدتها ومستوى مادة أنترليوكين-١ بيتا في السائل الزلالي للركبة وكذلك في الدم في مرضى الفصال العظمي للركبة.

وقد أجريت هذه الدراسة على ستين مريضا يعانون من الفصال العظمي لمفصل الركبة بالإضافة إلى ستة أشخاص كمجموعة ضابطة. وقد تم تقسيم حالات الفصال العظمي إلى ثلاث مجموعات:

المجموعة الأولى من المرضى يعالجون بواسطة دياسيرين لمدة شهرين بجرعة ٥٠ مجم كبسولة مرتين يوميا.

المجموعة الثانية من المرضى يعالجون بواسطة ديكلوفيناك صوديوم لمدة شهرين بجرعة ٧٥ مجم قرص مرة واحدة يوميا.

المجموعة الثالثة من المرضى يعالجون بواسطة الدوائين السابقين معا وبنفس الجرعات لمدة شهرين.

وقد تم تقييم شدة الألم وزمن المسافة التي يستطيع أن يمشيها المريض وتقدير نسبة تركيز مادة انترليوكين-١ بيتا، قبل وبعد شهر، وبعد شهرين من إعطاء العلاج لمرضى كل مجموعة من المجموعات الثلاث.

وقد اتضح أن شدة الألم وزمن المسافة التى يستطيع أن يمشيها المريض قد تحسنت بدرجة كبيرة بعد شهرين من تناول عقار دياسيرين حيث أصبح زمن المسافة التى يستطيع أن يمشيها المريض أقل فى المجموعة الأولى بعد شهرين مقارنة بالمجموعة الثالثة، ولكن لم يستطع عشرة من المرضى من استكمال البحث لنهايته من مرضى المجموعة الثانية.

ولم يتغير مستوى أنترليوكين-١ بيتا بدرجة مهمة إحصائيا بعد العلاج بعقار دياسيرين فى المجموعة الأولى والمجموعة الثالثة.

وبالنسبة لمستوى أنترليوكين-١ بيتا فى الدم، لم يوجد تغير ذو أهمية إحصائية بين المجموعات الثلاث قبل العلاج إلا أن مستوى أنترليوكين-١ بيتا فى الدم قد انخفض بدرجة مهمة إحصائيا فى المجموعة الثانية مقارنة بالمجموعة الأولى والمجموعة الثالثة بعد شهرين من العلاج.

الخلاصة:

يمكن استعمال دياسيرين فى التحكم فى شدة الألم الناتج عن حالات مرض الفصال العظمي للركبة التى لا تتحمل استعمال مضادات الالتهابات الغير ستيرودية والتى تتحمل استعمال دياسيرين.

التوصية:

نوصى بدراسة تمتد لستة أشهر إلى سنة على تأثير تخفيف الألم وقوة التحمل والآثار الجانبية لدياسيرين فى مرضى الفصال العظمى للركبة.

دراسة إكلينيكية على تأثير دياسيرين على آلام الركبة وشدتها ومستوى أنترليوكين -١ فى السائل الزلالى للركبة فى مرضى الفصال العظمى للركبة

رسالة علمية

مقدمة لكلية الطب – جامعة الإسكندرية
إيفاءاً جزئياً لشروط للحصول على درجة

دكتوراه فى الطب الطبيعى والروماتيزم والتأهيل

مقدمة من

أحمد عبد الخالق حافظ إبراهيم

بكالوريوس الطب والجراحة - جامعة أسيوط
ماجستير الطب الطبيعى والروماتيزم والتأهيل - جامعة أسيوط

كلية الطب
جامعة الإسكندرية
٢٠١٥

دراسة إكلينيكية على تأثير دياسيرين على آلام الركبة وشدتها ومستوى أنترليوكين -١ فى السائل الزلالى للركبة فى مرضى الفصال العظمى للركبة

مقدمة من

أحمد عبد الخالق حافظ إبراهيم

بكالوريوس الطب والجراحة - جامعة أسيوط
ماجستير الطب الطبيعى والروماتيزم والتأهيل - جامعة أسيوط

للحصول على درجة

دكتوراه فى الطب الطبيعى والروماتيزم والتأهيل

لجنة المناقشة والحكم على الرسالة	**موافقون**
أ.د/ طارق سعد شفشق أستاذ الطب الطبيعى والروماتيزم والتأهيل كلية الطب جامعة الإسكندرية	.....
أ.د/ ضياء فهمى محسب أستاذ الطب الطبيعى والروماتيزم والتأهيل كلية الطب جامعة الإسكندرية	.....
أ.د/ على عيد الديب أستاذ الطب الطبيعى والروماتيزم والتأهيل كلية الطب جامعة طنطا	.....

التاريخ:

السادة المشرفون

أ.د/ طارق سعد شفشق .....

أستاذ الطب الطبيعى والروماتيزم والتأهيل

كلية الطب

جامعة الإسكندرية

د/ إيناس محمد شاهين .....

أستاذ الطب الطبيعى والروماتيزم والتأهيل

كلية الطب

جامعة الإسكندرية

د/ نجلاء عبد المحسن محمد .....

أستاذ مساعد الطب الطبيعى والروماتيزم والتأهيل

كلية الطب

جامعة الإسكندرية

المشرف المشارك

د/ ريم عبد الحميد حرفوش .....

أستاذ مساعد الميكروبيولوجيا الطبية والمناعة

كلية الطب

جامعة الإسكندرية